Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 26, 2022; 10(18): 6184-6191
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6184
Published online Jun 26, 2022. doi: 10.12998/wjcc.v10.i18.6184
Toripalimab combined with targeted therapy and chemotherapy achieves pathologic complete response in gastric carcinoma: A case report
Rui Liu, Xia Wang, Zhi Ji, Ting Deng, Hong-Li Li, Yan-Hui Zhang, Yu-Chong Yang, Shao-Hua Ge, Le Zhang, Ming Bai, Tao Ning, Yi Ba, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300000, China
Author contributions: Liu R designed the experiments, processed the data, applied for fund support, and wrote the first draft; Wang X performed the data collection; Ji Z, Deng T, Li HL, Zhang YH, Yang YC, Ge SH, Zhang L, Bai M and Ning T performed the data analysis; Ba Y modified the article.
Supported by Chinese Research Hospital Association , No. Y2019FH-DTCC-SC3 .
Informed consent statement: Informed written consent was obtained from the patient for the publication of this report and any accompanying images.
Conflict-of-interest statement: Nothing to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rui Liu, Doctor, Chief Doctor, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, North Huanhu West Road, Sports Institute, Hexi District, Tianjin 300000, China. ruiliu688@126.com
Received: November 5, 2021
Peer-review started: November 5, 2021
First decision: February 14, 2022
Revised: February 28, 2022
Accepted: April 22, 2022
Article in press: April 22, 2022
Published online: June 26, 2022
Processing time: 223 Days and 22.3 Hours
Peer-review started: November 5, 2021
First decision: February 14, 2022
Revised: February 28, 2022
Accepted: April 22, 2022
Article in press: April 22, 2022
Published online: June 26, 2022
Processing time: 223 Days and 22.3 Hours
Core Tip
Core Tip: We report a case in which pathologic complete response was achieved by neoadjuvant administration of toripalimab, Herceptin, and docetaxel, oxaliplatin, calcium folinate, and fluorouracil chemo